NeuroMetrix (NASDAQ:NURO) versus Daxor (NASDAQ:DXR) Head to Head Contrast

NeuroMetrix (NASDAQ:NURO) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, earnings and profitability.

Volatility & Risk

NeuroMetrix has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500. Comparatively, Daxor has a beta of -0.21, suggesting that its stock price is 121% less volatile than the S&P 500.

Earnings and Valuation

This table compares NeuroMetrix and Daxor”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroMetrix	$3.03 million	3.09	-$6.53 million	($4.59)	-0.99
Daxor	$2.13 million	17.59	N/A	N/A	N/A

Daxor has lower revenue, but higher earnings than NeuroMetrix.

Analyst Recommendations

This is a breakdown of recent ratings for NeuroMetrix and Daxor, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroMetrix	0	0	0	0	0.00
Daxor	0	0	1	0	3.00

Daxor has a consensus target price of $25.00, indicating a potential upside of 222.58%. Given Daxor’s stronger consensus rating and higher possible upside, analysts plainly believe Daxor is more favorable than NeuroMetrix.

Profitability

This table compares NeuroMetrix and Daxor’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroMetrix	-203.71%	-42.56%	-39.26%
Daxor	N/A	N/A	N/A

Institutional & Insider Ownership

19.4% of NeuroMetrix shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 7.3% of NeuroMetrix shares are held by insiders. Comparatively, 59.0% of Daxor shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Daxor beats NeuroMetrix on 8 of the 11 factors compared between the two stocks.

About NeuroMetrix

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.